58110-89-7

Provided is a compound of the following Formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. Further, provided is a pharmaceutical composition for preventing or treating a metabolic syndrome or an inflammatory disease, including the same. in the formula, R1 is a hydrogen atom, methyl, methoxy, or a halogen atom; R2 is a hydrogen atom; a substituted or unsubstituted straight or branched C1-C6 alkyl group; a halogen atom; a substituted or unsubstituted straight or branched C1-C6 alkoxy group; or a substituted or unsubstituted straight or branched C1-C4 thioalkyl group; R3 and R4 are each independently a hydrogen atom, or a C1-C2 alkyl group; and in the case of the substituted alkyl, the substituted alkoxy, and the substituted thioalkyl, the substituent is a straight or branched C1-C5 alkyl group, a halogen atom, a straight or branched C1-C5 alkoxy group, or a straight or branched C1-C3 thioalkyl group.

Provided are a pyranochromenyl phenol derivative, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical composition for preventing or treating metabolic syndrome or inflammatory disease comprising same. The present invention is efficacious in preventing or treating metabolic syndrome or inflammatory disease and is chemically stable.

Bioactive natural products are a potential source of new pharmaceuticals since they offer new modes of action and more specific activities. The use of derivatization also enables the optimal structure for their biological activity to be determined. In thi

Figure presented. The natural p-naphthoquinone (-)-thespesone 1 and its (+)-enantiomer were synthesized for the first time by bisacylation of a 5-lithiodihydrobenzofuran 2′ with 4-methyl-3-tert-butoxycyclobut-3-ene-1, 2-dione 3. The racemate of the required 2-arylpropan-1-ol precursor 10 was kinetically resolved by an enzyme-catalyzed acetylation exclusively of the (S)-enantiomer. Saponification of this acetate mediated by the same enzyme, porcine pancreas lipase (PPL), afforded the (S)-2-arylpropan-1-ol in 96% ee. Its unreacted (R)-enantiomer could be obtained with 77% ee. (-)-(S)-Thespesone was far more efficacious against a panel of six cancer cell lines including multiresistant ones than its (+)-enantiomer and also when compared to thymoquinone, an established natural antitumoral p-quinone from Nigella sativa. Unlike the latter, (-)-thespesone was well tolerated by nonmalignant fibroblasts.

A total synthesis of natural bisabolane sesquiterpenes curcuphenol (1) and xanthorrhizol (2) was developed by using the substituted acetophenones 4 and 5, respectively, as starting materials. The acetyl group of the latter was activated through ethoxycarb

The total synthesis of paeonilide, a natural anti-PAF (platelet-activating factor) new skeleton monoterpenoid with an IC50 value of 8 μg/mL, was achieved in 16 steps with 15% overall yield from commercially available 2-hydroxy-4-methylacetophenone.

Activity-directed fractionation of a CH2Cl2-MeOH (1:1) extract of Hofmeisteria schaffneri led to the isolation of a new phytotoxin characterized as 2′-(2″-hydroxy-4″-methylphenyl)- 2′-oxoethyl acetate and designated the trivial name of hofmeisterin (1). In addition, the known compounds β-carotene, euparin, and 3′,4′,4a′,9a′-tetrahydro-6,7′- dimethylspiro[benzofuran-3(2H),2′-pyrano[2,3-b]benzofuran]-2, 4a′-diol (2) were obtained. The identification of the isolates was accomplished by spectroscopic methods. The structure of 1 was unequivocally confirmed by synthesis. The methyl derivative 1a was also synthesized following the same strategy. Compounds 1 and 2 inhibited radicle growth of Amaranthus hypochondriacus (IC50 = 3.2 × 10-4 and 1.2 × 10-5 M, respectively) and significantly inhibited activation of the calmodulin (CaM)-dependent enzyme cAMP phosphodiesterase (PDE) with IC 50 values of 4.4 and 4.22 μM, respectively.